Table 3.
Univariate analysis
| Variables | Disease free survival | Cancer specific survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95 % CI | P | HR | 95 % CI | P | HR | 95 % CI | P | |
| Gender [male versus female] |
1.213 | 0.59–2.48 | 0.596 | 1.152 | 0.67–1.96 | 0.602 | 1.063 | 0.70–1.60 | 0.770 |
| Age [≤66 versus >66 years] |
1.709 | 0.82–3.55 | 0.151 | 1.153 | 0.68–1.94 | 0.592 | 1.191 | 0.79–1.77 | 0.390 |
| Smoking status [never versus current/former] |
1.478 | 0.60–1.47 | 0.395 | 1.782 | 0.85 - 3.69 | 0.121 | 1.332 | 0.79–2.23 | 0.278 |
| Comorbidity [no versus yes] |
1.395 | 0.65–2.96 | 0.388 | - | - | - | - | - | - |
| ALK-CNGa
[Disomic/3-7 versus > 7] |
1.695 | 0.49–5.77 | 0.399 | 1.498 | 0.62–3.57 | 0.363 | 1.598 | 0.85–2.98 | 0.141 |
| Disease stage [I-II versus III] |
13.12 | 4.59–37.4 | <0.001 | - | - | - | - | - | - |
| T descriptor [1–2 versus 3–4] |
3.920 | 1.73–8.86 | 0.001 | - | - | - | - | - | - |
| N descriptor [0 versus 1] |
4.259 | 1.79–10.2 | 0.001 | - | - | - | - | - | - |
| Grading [1 versus 2 versus 3] |
2.128 3.390 |
0.42–10.6 0.73–15.6 |
0.357 0.117 |
- | - | - | - | - | - |
| Surgery [yes versus no] |
8.425 | 3.65–19.3 | <0.001 | - | - | - | - | - | - |
| Performance Status [0 versus 1 versus 2–3] |
- | - | - | 2.358 4.581 |
1.25–4.42 1.81–11.5 |
0.007 0.001 |
1.647 3.864 |
1.00–2.70 1.98–7.52 |
0.049 <0.001 |
| Synchronous Metastases [no versus yes] |
- | - | - | 1.119 | 0.15–8.14 | 0.912 | 2.335 | 1.52–3.58 | <0.001 |
| Response rate to 1st line [yes versus no] |
- | - | - | - | - | - | 2.356 | 1.31–4.23 | 0.004 |
HR hazard ratios, CI confidence intervals, CNG copy number gain
aThe results of the univariate analysis are not significant even categorizing individually the variables [disomic versus 3–7 versus > 7]